NYSE:GSK - US37733W2044 - ADR
TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
---|---|---|---|---|---|---|---|---|
Revenue | 31.63B | 31.38B | 30.33B | 29.32B | 24.70B | |||
Minority Interest Expense | -561.00M | -376.00M | -380.00M | -665.00M | -711.00M | |||
Cost Of Goods | 8.93B | 8.82B | 8.36B | 8.47B | 8.01B | |||
Gross Profit | 22.70B | 22.56B | 21.96B | 20.86B | 16.69B | |||
Operating Expenses | 14.72B | 14.42B | 13.66B | 12.46B | 10.94B | |||
Research and Development | 6.15B | 6.02B | 5.75B | 5.06B | 4.53B | |||
Selling, General, and Administrative Expenses | 8.93B | 8.97B | 9.03B | 8.13B | 6.75B | |||
Operating Income | 7.99B | 8.14B | 8.30B | 8.39B | 5.75B | |||
Interest Income/Expense | -508.00M | -2.54B | -1.29B | -1.44B | -2.36B | |||
Other Income/Expense | N/A | 218.00M | -48.00M | -799.00M | 561.00M | |||
Non Recurring Items | -2.86B | -2.34B | -897.00M | -529.00M | -355.00M | |||
Income Before Taxes | 4.62B | 3.48B | 6.06B | 5.63B | 3.60B | |||
Income Tax | 638.00M | 526.00M | 756.00M | 707.00M | 83.00M | |||
Net Income | 3.42B | 2.58B | 4.93B | 14.96B | 4.38B | |||
EBITDA | 11.74B | 10.69B | 10.60B | 10.54B | 8.13B | |||
Per Share Data | ||||||||
EPS Diluted Total Ops | 1.69 | 1.27 | 2.44 | 7.46 | 2.20 | |||
Non GAAP EPS | 3.35 | 3.25 | 3.16 | 3.02 | 2.89 | |||
Statistics | ||||||||
Gross Profit Margin | 71.77% | 71.90% | 72.42% | 71.13% | 67.58% | |||
Profit Margin | 10.82% | 8.21% | 16.25% | 51.00% | 17.76% | |||
Operating Profit Margin | 25.25% | 25.93% | 27.38% | 28.63% | 23.28% |
All data in GBP